Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more
Corcept Therapeutics Incorporated (CORT) - Net Assets
Latest net assets as of December 2025: $647.80 Million USD
Based on the latest financial reports, Corcept Therapeutics Incorporated (CORT) has net assets worth $647.80 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($836.65 Million) and total liabilities ($188.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $647.80 Million |
| % of Total Assets | 77.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | 72.38% |
| 10-Year Change | 1465.54% |
| Growth Volatility | 124.16 |
Corcept Therapeutics Incorporated - Net Assets Trend (2000–2025)
This chart illustrates how Corcept Therapeutics Incorporated's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Corcept Therapeutics Incorporated (2000–2025)
The table below shows the annual net assets of Corcept Therapeutics Incorporated from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $647.80 Million | -4.68% |
| 2024-12-31 | $679.59 Million | +34.12% |
| 2023-12-31 | $506.70 Million | +0.97% |
| 2022-12-31 | $501.84 Million | +33.54% |
| 2021-12-31 | $375.81 Million | -28.19% |
| 2020-12-31 | $523.34 Million | +40.99% |
| 2019-12-31 | $371.18 Million | +34.54% |
| 2018-12-31 | $275.88 Million | +44.47% |
| 2017-12-31 | $190.97 Million | +361.51% |
| 2016-12-31 | $41.38 Million | +123.69% |
| 2015-12-31 | $18.50 Million | +645.99% |
| 2014-12-31 | $-3.39 Million | -116.12% |
| 2013-12-31 | $21.02 Million | -65.98% |
| 2012-12-31 | $61.78 Million | +77.48% |
| 2011-12-31 | $34.81 Million | +63.84% |
| 2010-12-31 | $21.24 Million | -3.84% |
| 2009-12-31 | $22.09 Million | +30.67% |
| 2008-12-31 | $16.91 Million | +14.75% |
| 2007-12-31 | $14.73 Million | +131.67% |
| 2006-12-31 | $6.36 Million | -76.08% |
| 2005-12-31 | $26.59 Million | -42.12% |
| 2004-12-31 | $45.95 Million | +348.56% |
| 2003-12-31 | $10.24 Million | +146.69% |
| 2002-12-31 | $-21.94 Million | -198.06% |
| 2001-12-31 | $22.38 Million | +11515.82% |
| 2000-12-31 | $-196.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Corcept Therapeutics Incorporated's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 64338700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $643.39 Million | 99.32% |
| Common Stock | $140.00K | 0.02% |
| Other Comprehensive Income | $2.26 Million | 0.35% |
| Other Components | $2.01 Million | 0.31% |
| Total Equity | $647.80 Million | 100.00% |
Corcept Therapeutics Incorporated Competitors by Market Cap
The table below lists competitors of Corcept Therapeutics Incorporated ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gruma SAB de CV
OTCGREY:GPAGF
|
$2.96 Billion |
|
H B Fuller Company
NYSE:FUL
|
$2.96 Billion |
|
Community Bank System Inc
NYSE:CBU
|
$2.96 Billion |
|
Nisshin Seifun Group Inc
F:NFR
|
$2.97 Billion |
|
INDIVIOR PLC DL 050
F:2IVB
|
$2.96 Billion |
|
Oil India Limited
NSE:OIL
|
$2.95 Billion |
|
Demant A/S
PINK:WILLF
|
$2.95 Billion |
|
PotlatchDeltic Corp
NASDAQ:PCH
|
$2.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Corcept Therapeutics Incorporated's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 679,589,000 to 647,805,000, a change of -31,784,000 (-4.7%).
- Net income of 99,652,000 contributed positively to equity growth.
- Share repurchases of 245,856,000 reduced equity.
- Other comprehensive income increased equity by 2,481,000.
- Other factors increased equity by 111,939,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $99.65 Million | +15.38% |
| Share Repurchases | $245.86 Million | -37.95% |
| Other Comprehensive Income | $2.48 Million | +0.38% |
| Other Changes | $111.94 Million | +17.28% |
| Total Change | $- | -4.68% |
Book Value vs Market Value Analysis
This analysis compares Corcept Therapeutics Incorporated's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.05x to 6.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $4.16 | $33.51 | x |
| 2002-12-31 | $-3.26 | $33.51 | x |
| 2003-12-31 | $1.18 | $33.51 | x |
| 2004-12-31 | $2.49 | $33.51 | x |
| 2005-12-31 | $1.18 | $33.51 | x |
| 2006-12-31 | $0.28 | $33.51 | x |
| 2007-12-31 | $0.43 | $33.51 | x |
| 2008-12-31 | $0.36 | $33.51 | x |
| 2009-12-31 | $0.42 | $33.51 | x |
| 2010-12-31 | $0.31 | $33.51 | x |
| 2011-12-31 | $0.42 | $33.51 | x |
| 2012-12-31 | $0.66 | $33.51 | x |
| 2013-12-31 | $0.21 | $33.51 | x |
| 2014-12-31 | $-0.03 | $33.51 | x |
| 2015-12-31 | $0.17 | $33.51 | x |
| 2016-12-31 | $0.36 | $33.51 | x |
| 2017-12-31 | $1.53 | $33.51 | x |
| 2018-12-31 | $2.18 | $33.51 | x |
| 2019-12-31 | $3.03 | $33.51 | x |
| 2020-12-31 | $4.21 | $33.51 | x |
| 2021-12-31 | $2.98 | $33.51 | x |
| 2022-12-31 | $4.33 | $33.51 | x |
| 2023-12-31 | $4.53 | $33.51 | x |
| 2024-12-31 | $5.99 | $33.51 | x |
| 2025-12-31 | $5.40 | $33.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Corcept Therapeutics Incorporated utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.38%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.09%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 1.29x
- Recent ROE (15.38%) is above the historical average (-47.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -33.31% | 0.00% | 0.00x | 1.08x | $-9.69 Million |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.31 Million |
| 2003 | -95.79% | 0.00% | 0.00x | 1.15x | $-10.84 Million |
| 2004 | -33.81% | 0.00% | 0.00x | 1.04x | $-20.13 Million |
| 2005 | -75.56% | 0.00% | 0.00x | 1.13x | $-22.75 Million |
| 2006 | -391.08% | -8460.20% | 0.03x | 1.56x | $-25.51 Million |
| 2007 | -78.55% | -2401.04% | 0.03x | 1.20x | $-13.05 Million |
| 2008 | -118.65% | -9598.56% | 0.01x | 1.17x | $-21.75 Million |
| 2009 | -91.28% | -69537.93% | 0.00x | 1.11x | $-22.38 Million |
| 2010 | -122.23% | 0.00% | 0.00x | 1.18x | $-28.09 Million |
| 2011 | -92.95% | 0.00% | 0.00x | 1.14x | $-35.83 Million |
| 2012 | -61.59% | -1150.53% | 0.03x | 1.61x | $-44.23 Million |
| 2013 | -218.92% | -444.25% | 0.16x | 3.00x | $-48.11 Million |
| 2014 | 0.00% | -118.20% | 0.77x | 0.00x | $-31.04 Million |
| 2015 | -34.64% | -12.74% | 0.97x | 2.81x | $-8.26 Million |
| 2016 | 19.67% | 10.01% | 1.18x | 1.66x | $4.00 Million |
| 2017 | 67.61% | 81.11% | 0.72x | 1.15x | $110.03 Million |
| 2018 | 27.33% | 30.01% | 0.81x | 1.13x | $47.82 Million |
| 2019 | 25.37% | 30.73% | 0.74x | 1.11x | $57.06 Million |
| 2020 | 20.26% | 29.96% | 0.62x | 1.09x | $53.68 Million |
| 2021 | 29.94% | 30.74% | 0.86x | 1.13x | $74.93 Million |
| 2022 | 20.21% | 25.24% | 0.69x | 1.16x | $51.23 Million |
| 2023 | 20.95% | 22.00% | 0.78x | 1.23x | $55.47 Million |
| 2024 | 20.56% | 20.70% | 0.80x | 1.24x | $71.77 Million |
| 2025 | 15.38% | 13.09% | 0.91x | 1.29x | $34.87 Million |
Industry Comparison
This section compares Corcept Therapeutics Incorporated's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Corcept Therapeutics Incorporated (CORT) | $647.80 Million | -33.31% | 0.29x | $2.96 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |